The number of cancer cases continues to rise worldwide, and detection is occurring earlier and earlier. In this context, precision medicine is no longer optional — it has become essential. Tailoring treatments to the specific characteristics of each patient is key to improving survival rates and quality of life.

ScreenCell® is fully committed to this approach by developing single-use devices designed to isolate circulating tumor cells (CTCs) from a simple blood sample. Our liquid biopsy technology offers a non-invasive and cost-effective alternative for accessing valuable insights into the disease, enabling cytological analyses, molecular biology studies, and even the culture of circulating tumor cells.

With over 15 years of experience, ScreenCell® markets its products internationally and is part of a strong collaborative network within the scientific and medical communities. To date, more than 70,000 filtration units have been sold worldwide, and over 70 scientific publications have validated the effectiveness of our technology.

Follow our page to stay up to date with our latest news, publications, clinical studies, and partnership opportunities. Together, let's advance personalized medicine!

ScreenCell

Org chart

Teams

Offices